{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:16:35Z","timestamp":1776816995670,"version":"3.51.2"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>Emerging data have suggested that sirolimus may be a treatment option for complicated vascular anomalies (VAs). The present study aimed to investigate the immunologic effects of sirolimus treatment for 6 months in patients with VAs. Blood samples obtained from the patients enrolled in 2 multicenter studies to investigate the efficacy of sirolimus for VAs before and after sirolimus treatment for 6 months were used. Data for total white blood cell count, absolute lymphocyte count, serum immunoglobulins (Igs) levels (IgG, IgA, IgM), lymphocyte proliferation assays with mitogens including phytohemagglutinin and concanavalin A, and flow cytometric analysis of lymphocyte subsets were evaluated. A total of 18 patients with VAs receiving sirolimus treatment were included in the study. Comparisons of white blood cell, absolute lymphocyte count, IgG, IgA, IgM, and reaction rates of phytohemagglutinin and concanavalin A revealed no significant differences before and after treatment. No significant differences were observed in the absolute counts of lymphocyte subtypes before and after treatment, except for regulatory T-cell counts, which were significantly decreased after treatment. Severe infections were not observed during sirolimus treatment. The immunologic parameters assessed in the present study were hardly affected by sirolimus treatment for 6 months in patients with VAs.<\/jats:p>","DOI":"10.1097\/mph.0000000000001650","type":"journal-article","created":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T23:37:18Z","timestamp":1574033838000},"page":"e355-e360","source":"Crossref","is-referenced-by-count":7,"title":["Immunologic Effects of Sirolimus in Patients With Vascular Anomalies"],"prefix":"10.1097","volume":"42","author":[{"given":"Akifumi","family":"Nozawa","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Ozeki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiho","family":"Yasue","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Kawamoto","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Ohnishi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigehisa","family":"Fumino","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Kyoto Prefectural University of Medicine, Kyoto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taizo","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Kyoto Prefectural University of Medicine, Kyoto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuro","family":"Tajiri","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Kyoto Prefectural University of Medicine, Kyoto"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanobu","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Department of General Pediatrics and Interdisciplinary Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Fujino","sequence":"additional","affiliation":[{"name":"Department of Surgical Subspecialties, Division of Surgery, National Center for Child Health and Development, Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Souzaki","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Developmental Surgery and Intestinal Transplant Surgery, Kyushu University Hospital, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Fukao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1542\/peds.2014-3673","article-title":"Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies","volume":"136","author":"Wassef","year":"2015","journal-title":"Pediatrics"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.hoc.2019.01.011","article-title":"Vascular anomalies: diagnosis of complicated anomalies and new medical treatment options","volume":"33","author":"Adams","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/pbc.23124","article-title":"Sirolimus for the treatment of complicated vascular anomalies in children","volume":"57","author":"Hammill","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"e20153257","DOI":"10.1542\/peds.2015-3257","article-title":"Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies","volume":"137","author":"Adams","year":"2016","journal-title":"Pediatrics"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13023-018-0934-z","article-title":"Sirolimus is efficacious in treatment for extensive and\/or complex slow-flow vascular malformations: a monocentric prospective phase II study","volume":"13","author":"Hammer","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5500\/wjt.v6.i1.183","article-title":"Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation","volume":"6","author":"Baroja-Mazo","year":"2016","journal-title":"World J Transplant"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1542\/peds.2016-2919","article-title":"A case report of 2 sirolimus-related deaths among infants with kaposiform hemangioendotheliomas","volume":"141","author":"Ying","year":"2018","journal-title":"Pediatrics"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1542\/peds.2017-1044","article-title":"Pneumocystis Jirovecii pneumonia during sirolimus therapy for kaposiform hemangioendothelioma","volume":"141","author":"Russell","year":"2018","journal-title":"Pediatrics"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.reth.2018.12.001","article-title":"Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: a study protocol for an open-label, single-arm, multicenter, prospective study (SILA)","volume":"10","author":"Ozeki","year":"2019","journal-title":"Regen Ther"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20060772","article-title":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells","volume":"20","author":"Liu","year":"2006","journal-title":"J Exp Med"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nyas.12756","article-title":"mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging","volume":"1346","author":"Perl","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev-immunol-020711-075024","article-title":"Regulation of immune responses by mTOR","volume":"30","author":"Powell","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signalling in T cell fate decisions","volume":"12","author":"Chi","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.immuni.2010.09.002","article-title":"The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism","volume":"33","author":"Powell","year":"2010","journal-title":"Immunity"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08155","article-title":"mTOR regulates memory CD8 T-cell differentiation","volume":"460","author":"Araki","year":"2009","journal-title":"Nature"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.immuni.2009.04.014","article-title":"The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment","volume":"30","author":"Delgoffe","year":"2009","journal-title":"Immunity"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/ni.1760","article-title":"Foxp3+ regulatory T cells: differentiation, specification, subphenotypes","volume":"10","author":"Feuerer","year":"2009","journal-title":"Nat Immunol"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fimmu.2019.00043","article-title":"Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity","volume":"10","author":"Romano","year":"2019","journal-title":"Front Immunol"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.coi.2015.09.002","article-title":"Targeting Treg signaling for the treatment of autoimmune diseases","volume":"37","author":"Spence","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.4049\/jimmunol.177.12.8338","article-title":"Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients","volume":"177","author":"Battaglia","year":"2006","journal-title":"J Immunol"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.msard.2018.08.009","article-title":"Promising effect of rapamycin on multiple sclerosis","volume":"26","author":"Bagherpour","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4049\/jimmunol.178.1.320","article-title":"Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin","volume":"178","author":"Strauss","year":"2007","journal-title":"J Immunol"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00262-008-0602-6","article-title":"Apoptosis of CD4(+)CD25(high) T cells in response to sirolimus requires activation of T cell receptor and is modulated by IL-2","volume":"58","author":"Molhoek","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1055\/s-2008-1063852","article-title":"Pneumocystis pneumonia","volume":"29","author":"D\u2019Avignon","year":"2008","journal-title":"Semin Respir Crit Care Med"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.4049\/jimmunol.177.9.6215","article-title":"Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of pneumocystis pneumonia","volume":"177","author":"McKinley","year":"2006","journal-title":"J Immunol"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/1521-4141(200205)32:5<1282::AID-IMMU1282>3.0.CO;2-#","article-title":"CD25+CD4+ regulatory T cells suppress CD4+ T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice","volume":"32","author":"Hori","year":"2002","journal-title":"Eur J Immunol"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1128\/IAI.70.11.6107-6113.2002","article-title":"Local delivery of the viral interleukin-10 gene suppresses tissue inflammation in murine Pneumocystis carinii infection","volume":"70","author":"Ruan","year":"2002","journal-title":"Infect Immun"},{"key":"R30-20230918","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1097\/TP.0b013e3181874a36","article-title":"Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin","volume":"86","author":"Heidt","year":"2008","journal-title":"Transplantation"},{"key":"R31-20230918","doi-asserted-by":"crossref","first-page":"e0129658","DOI":"10.1371\/journal.pone.0129658","article-title":"Differential effects of tacrolimus versus sirolimus on the proliferation, activation and differentiation of human B cells","volume":"10","author":"Traitanon","year":"2015","journal-title":"PLoS One"},{"key":"R32-20230918","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.2217\/IMT.15.74","article-title":"Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities","volume":"7","author":"Eibl","year":"2015","journal-title":"Immunotherapy"},{"key":"R33-20230918","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1749-6632.2003.tb06044.x","article-title":"Hypermutation in human B cells in vivo and in vitro","volume":"987","author":"Weller","year":"2003","journal-title":"Ann N Y Acad Sci"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:48:52Z","timestamp":1695012532000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001650","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,14]]}}}